Alnylam Pharmaceuticals, Inc.
Isis Pharmaceuticals enters RNAi alliance
Published in Pharma Investments, Ventures and Law Weekly, April 11th, 2004
The alliance combines Isis' intellectual property and development expertise with Alnylam's intellectual property and research expertise in RNAi therapeutics. The alliance provides Isis with an opportunity to realize significant value from its work in antisense mechanisms and oligonucleotide chemistry and strengthens Alnylam's RNAi therapeutics discovery and commercialization efforts.
"We are confident that Alnylam...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- AVI BioPharma, Inc.
Neugene maker reports quarterly loss of $0.10 per share - Alfacell Corporation
Savadelis named chief financial officer at pharmaceutical firm - American Oriental Bioengineering
Bioengineering firm expects record revenue growth, income for 2003 - Aspreva Pharmaceuticals Corp.
Autoimmune disease drug maker completes raises $57 million - Avitar, Inc.
Diagnostics company announces second closing of private placement - BioRexis Pharmaceutical Corp.
Biopharmaceutical firm completes $30M series B financing - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
